Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.08 USD | -0.55% | +4.67% | -14.66% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.66% | 2.53B | |
+29.26% | 49.46B | |
+0.54% | 42.58B | |
+48.94% | 42.49B | |
-5.26% | 29.09B | |
+12.24% | 26.61B | |
-24.12% | 18.64B | |
+7.57% | 13.16B | |
+31.96% | 12.55B | |
+24.12% | 12.1B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- RBC Cuts Intellia Therapeutics' Price Target to $90 From $100, Keeps Outperform Speculative Risk Rating